Cariprazine, sold as Vraylar in the US (Reagila in Europe), was approved by the FDA in 2015 for schizophrenia and acute manic or mixed episodes of bipolar I disorder, with later approvals for bipolar depression and as adjunctive treatment for major depressive disorder. It is in the same partial-agonist family as aripiprazole and brexpiprazole, but with two distinguishing features that shape the experience of taking it: a strong preference for the dopamine D3 receptor over D2, and an exceptionally long half-life.
Cariprazine is a once-daily partial agonist at dopamine D3 and D2 receptors with a half-life measured in weeks, FDA-approved for schizophrenia, bipolar mania, bipolar depression, and adjunctive MDD, with notable potential benefit for negative symptoms.
What "D3-preferring" means in practice
Most antipsychotics target the dopamine D2 receptor, which is most densely expressed in the striatum (relevant to positive symptoms and EPS). The D3 receptor is concentrated in limbic regions and the prefrontal cortex — areas thought to underlie motivation, reward, and negative/cognitive symptoms. Cariprazine binds D3 about ten times more strongly than D2. The hypothesis is that this profile may help with negative symptoms, where most antipsychotics struggle. A randomised double-blind trial published in The Lancet in 2017 (Németh et al.) found cariprazine modestly more effective than risperidone for predominantly negative symptoms — one of few positive trials for any antipsychotic in this domain.
The very long half-life
Cariprazine is unusual because its main active metabolite (didesmethyl cariprazine) has a half-life of 1 to 3 weeks. Steady state takes weeks to reach, and even after stopping, drug levels persist for weeks. Practical implications:
- Effect builds gradually — judging response at 4 weeks may underestimate eventual benefit
- Missed doses have less acute impact than with shorter-half-life drugs
- Side effects can also persist after stopping
- Switching off cariprazine takes time for the body to clear
FDA-approved indications
- Schizophrenia in adults — acute and maintenance
- Bipolar I mania — acute manic or mixed episodes
- Bipolar I depression — depressive episodes
- Adjunctive treatment of major depressive disorder — added in 2022
Dosing
For schizophrenia, the FDA-recommended starting dose per the Vraylar prescribing information is 1.5 mg once daily, increased to 3 mg on day 2. Further increases of 1.5 to 3 mg can be made based on response and tolerability, up to 6 mg/day. For bipolar mania, doses up to 6 mg/day are typical; for bipolar depression and MDD adjunct, lower doses (1.5 to 3 mg) are usually sufficient. Cariprazine can be taken with or without food.
Side effect profile
Akathisia
The most prominent side effect, particularly at higher doses. Many patients describe it as the limiting factor. Strategies include slow titration, dose reduction, propranolol, or a benzodiazepine if needed. See our akathisia management guide.
EPS
Tremor, stiffness, and parkinsonism occur but generally less than with high-potency typicals.
Insomnia and restlessness
Some patients find cariprazine activating, particularly early on. Dosing in the morning can help.
Nausea, indigestion, constipation
Common but usually mild and improve over the first weeks.
Weight gain and metabolic effects
Modest. Generally less than olanzapine or quetiapine, similar to aripiprazole. Standard metabolic monitoring still applies.
Compulsive behaviours
Like other partial agonists, cariprazine has occasional reports of pathological gambling, hypersexuality, and compulsive eating or shopping. The risk is thought to be related to the D3 partial agonism. Anyone starting cariprazine should be alerted to watch for these.
Class warnings
Cariprazine carries the standard antipsychotic boxed warning about increased mortality in elderly patients with dementia-related psychosis. It also carries class warnings about NMS, tardive dyskinesia, metabolic effects, and orthostatic hypotension.
Fever with severe muscle stiffness, sudden new involuntary movements, or thoughts of self-harm — call 988 in the US or your local emergency number.
Drug interactions
Cariprazine is metabolised primarily by CYP3A4. Strong CYP3A4 inhibitors (clarithromycin, itraconazole, grapefruit juice in large amounts) require dose reduction; strong CYP3A4 inducers should be avoided. The long half-life means interactions persist after stopping interacting drugs.
Who tends to do well on cariprazine
- People with prominent negative symptoms looking for an option with mechanistic plausibility
- People with bipolar I needing both schizophrenia-style symptom coverage and depression treatment
- People who responded to but couldn't tolerate aripiprazole — cariprazine has a different feel
- People who occasionally miss doses (the long half-life is forgiving)
Who might choose differently
- People with prior severe akathisia on partial agonists
- People in acute crisis needing rapid stabilisation (the long half-life works against speed)
- People for whom cost is prohibitive — Vraylar is brand-only in the US
- People taking strong CYP3A4 inducers that cannot be changed
Practical questions to ask your prescriber
- What dose are we targeting, and how long should we wait to judge response?
- Is cariprazine covered by my insurance?
- What should I do if I notice akathisia?
- How will the long half-life affect what happens if we stop or switch?
- What metabolic monitoring will we do?
The big picture
Cariprazine is a thoughtful choice for several patient profiles — particularly those for whom negative symptoms are prominent and where the ability to tolerate slow build-up is preserved. The long half-life is both a feature and a bug; it forgives missed doses but slows everything down. Akathisia is the most common reason cariprazine doesn't work out for individual patients, and worth watching closely. As with every antipsychotic decision, the right call depends on your symptom profile, prior responses, side effect tolerance, and insurance situation, weighed carefully with a prescriber who knows you.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.